453 related articles for article (PubMed ID: 27645344)
1. Influenza vaccination increases anti-JC virus antibody levels during treatment with Natalizumab: Case report.
Miranda Acuña JA; Weinstock-Guttman B
Mult Scler Relat Disord; 2016 Sep; 9():54-5. PubMed ID: 27645344
[TBL] [Abstract][Full Text] [Related]
2. High cumulative JC virus seroconversion rate during long-term use of natalizumab.
Vennegoor A; van Rossum JA; Leurs C; Wattjes MP; Rispens T; Murk JL; Uitdehaag BM; Killestein J
Eur J Neurol; 2016 Jun; 23(6):1079-85. PubMed ID: 27018481
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.
Vennegoor A; van Rossum JA; Polman CH; Wattjes MP; Killestein J
Mult Scler; 2015 Oct; 21(12):1600-3. PubMed ID: 25662344
[TBL] [Abstract][Full Text] [Related]
4. Changes in Anti-JCV Antibody Status in a Large Population of Multiple Sclerosis Patients Treated with Natalizumab.
Sgarlata E; Chisari CG; D'Amico E; Millefiorini E; Patti F
CNS Drugs; 2020 May; 34(5):535-543. PubMed ID: 32221861
[TBL] [Abstract][Full Text] [Related]
5. Association between soluble L-selectin and anti-JCV antibodies in natalizumab-treated relapsing-remitting MS patients.
Basnyat P; Hagman S; Kolasa M; Koivisto K; Verkkoniemi-Ahola A; Airas L; Elovaara I
Mult Scler Relat Disord; 2015 Jul; 4(4):334-8. PubMed ID: 26195052
[TBL] [Abstract][Full Text] [Related]
6. JCV serology in time: 3 years of follow-up.
Cambron M; Hadhoum N; Duhin E; Lacour A; Chouraki A; Vermersch P
Acta Neurol Scand; 2017 Jul; 136(1):54-58. PubMed ID: 27766611
[TBL] [Abstract][Full Text] [Related]
7. Anti-JCV antibody serostatus and longitudinal evaluation in a Portuguese Multiple Sclerosis population.
Correia I; Jesus-Ribeiro J; Batista S; Martins AI; Nunes C; Macário MC; Cunha L; Sousa L
J Clin Neurosci; 2017 Nov; 45():257-260. PubMed ID: 28844615
[TBL] [Abstract][Full Text] [Related]
8. John Cunningham Virus Status, Seroconversion Rate, and the Risk of Progressive Multifocal Leukoencephalopathy in Polish John Cunningham Virus-Seronegative Patients with Relapsing-Remitting Multiple Sclerosis.
Kapica-Topczewska K; Collin F; Tarasiuk J; Czarnowska A; Chorąży M; Mirończuk A; Kochanowicz J; Kułakowska A
Eur Neurol; 2020; 83(5):487-492. PubMed ID: 33027785
[TBL] [Abstract][Full Text] [Related]
9. Natalizumab-treated patients at high risk for PML persistently excrete JC polyomavirus.
Werner MH; Huang D
J Neurovirol; 2016 Dec; 22(6):871-875. PubMed ID: 27198748
[TBL] [Abstract][Full Text] [Related]
10. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
[TBL] [Abstract][Full Text] [Related]
11. The clinical utility of JC virus antibody index measurements in the context of progressive multifocal leukoencephalopathy.
Reuwer AQ; Heron M; van der Dussen D; Schneider-Hohendorf T; Murk JL
Acta Neurol Scand; 2017 Nov; 136 Suppl 201():37-44. PubMed ID: 29068484
[TBL] [Abstract][Full Text] [Related]
12. JC polyomavirus expression and bell-shaped regulation of its SF2/ASF suppressor during the follow-up of multiple sclerosis patients treated with natalizumab.
Uleri E; Ibba G; Piu C; Caocci M; Leoni S; Arru G; Serra C; Sechi G; Dolei A
J Neurovirol; 2017 Apr; 23(2):226-238. PubMed ID: 27812788
[TBL] [Abstract][Full Text] [Related]
13. JCPyV microRNA in plasma inversely correlates with JCPyV seropositivity among long-term natalizumab-treated relapsing-remitting multiple sclerosis patients.
Basnyat P; Virtanen E; Elovaara I; Hagman S; Auvinen E
J Neurovirol; 2017 Oct; 23(5):734-741. PubMed ID: 28831768
[TBL] [Abstract][Full Text] [Related]
14. Natalizumab is effective in controlling the inflammatory rebound after its discontinuation and failure of an alternative treatment.
Barroso B; Miquel M; Marasescu R; Demasles S; Krim E; Bonnan M
Mult Scler Relat Disord; 2015 Jul; 4(4):380-2. PubMed ID: 26195060
[TBL] [Abstract][Full Text] [Related]
15. Considerations for characterizing the risk of PML in natalizumab-treated patients.
Koendgen H; Ho PR; Chang I
Mult Scler Relat Disord; 2016 Sep; 9():121. PubMed ID: 27645357
[No Abstract] [Full Text] [Related]
16. Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biological sero-converters.
Schwab N; Schneider-Hohendorf T; Hoyt T; Gross CC; Meuth SG; Klotz L; Foley JF; Wiendl H
Mult Scler; 2018 Apr; 24(5):563-573. PubMed ID: 28847222
[TBL] [Abstract][Full Text] [Related]
17. The effect of plasma exchange on serum anti-JC virus antibodies.
Subramanyam M; Plavina T; Khatri BO; Fox RJ; Goelz SE
Mult Scler; 2013 Jun; 19(7):912-9. PubMed ID: 23232602
[TBL] [Abstract][Full Text] [Related]
18. Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.
Wijburg MT; Kleerekooper I; Lissenberg-Witte BI; de Vos M; Warnke C; Uitdehaag BMJ; Barkhof F; Killestein J; Wattjes MP
JAMA Neurol; 2018 Jul; 75(7):827-833. PubMed ID: 29532061
[TBL] [Abstract][Full Text] [Related]
19. Study of the anti-JCV antibody levels in a Spanish multiple sclerosis cohort.
Dominguez-Mozo MI; Rus M; Santiago JL; Izquierdo G; Casanova I; Galan V; Garcia-Martinez MA; Arias-Leal AM; García-Montojo M; Pérez-Pérez S; Arroyo R; Alvarez-Lafuente R
Eur J Clin Invest; 2017 Feb; 47(2):158-166. PubMed ID: 28036121
[TBL] [Abstract][Full Text] [Related]
20. JC-virus seroconversion in multiple sclerosis patients receiving natalizumab.
Outteryck O; Zéphir H; Salleron J; Ongagna JC; Etxeberria A; Collongues N; Lacour A; Fleury MC; Blanc F; Giroux M; de Seze J; Vermersch P
Mult Scler; 2014 Jun; 20(7):822-9. PubMed ID: 24072722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
